MedTrace Logo

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-08-03

No results posted yet for this study

Summary

The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Conditions

Interventions

DRUG

0.1 mg/kg Dimethyltryptamine (DMT)

0.1 mg/kg DMT

DRUG

0.3 mg/kg Dimethyltryptamine (DMT)

0.3 mg/kg DMT

Sponsors & Collaborators

  • Yale University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2026-07-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711915 on ClinicalTrials.gov